QIAGEN Midi Prep - Search Videos

Retsch Qiagen Tissuelyser II Sample Disruptor with Tube Adapter

Retsch Qiagen Tissuelyser II Sample Disruptor with Tube Adapter

YouTubeAlternative Lab Source

We exceeded our outlook for Q3 2025, raised our FY 2025 adjusted EPS target, announced the Parse acquisition and $500 million share repurchase to be completed in early January 2026. Learn more 👉 https://tinyurl.com/4292kbap ◾ Q3 2025 results: Net sales of $533 million ( 6% at actual rates); diluted EPS $0.60 ➡ Core sales 6% CER (constant exchange rates) driven by QIAstat-Dx ( 11% CER), QuantiFERON ( 11% CER) and Sample technologies ( 3% CER) ➡ Adj. operating income margin steady at 29.6% ➡ Adju

We exceeded our outlook for Q3 2025, raised our FY 2025 adjusted …

559 views1 week ago

We Think Qiagen's (NYSE:QGEN) Profit Is Only A Baseline For What They Can Achieve

We Think Qiagen's (NYSE:QGEN) Profit Is Only A Baseline For Wha…

YahooSimply Wall St

See more videos